SBIO.L vs. FWRA.L
SBIO.L (Invesco Nasdaq Biotech UCITS ETF) and FWRA.L (Invesco FTSE All-World UCITS ETF USD Accumulation) are both exchange-traded funds - SBIO.L is a Health & Biotech Equities fund tracking the NASDAQ Biotechnology TR USD, while FWRA.L is a Global Equities fund tracking the FTSE All-World Index. Both are passively managed. Over the past year, SBIO.L returned 41.44% vs 28.36% for FWRA.L. A 0.55 correlation means they provide meaningful diversification when combined. SBIO.L charges 0.40%/yr vs 0.15%/yr for FWRA.L.
Performance
SBIO.L vs. FWRA.L - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, SBIO.L achieves a 4.34% return, which is significantly lower than FWRA.L's 11.59% return.
SBIO.L
- 1D
- 3.10%
- 1M
- -0.64%
- YTD
- 4.34%
- 6M
- 3.70%
- 1Y
- 41.44%
- 3Y*
- 12.99%
- 5Y*
- 4.66%
- 10Y*
- 7.49%
FWRA.L
- 1D
- -0.13%
- 1M
- 2.52%
- YTD
- 11.59%
- 6M
- 12.75%
- 1Y
- 28.36%
- 3Y*
- —
- 5Y*
- —
- 10Y*
- —
SBIO.L vs. FWRA.L - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | |
|---|---|---|---|---|
SBIO.L Invesco Nasdaq Biotech UCITS ETF | 4.34% | 32.89% | -2.00% | 8.93% |
FWRA.L Invesco FTSE All-World UCITS ETF USD Accumulation | 11.59% | 22.37% | 18.07% | 9.23% |
Correlation
The correlation between SBIO.L and FWRA.L is 0.50, which is moderate. They share some common price drivers but move independently often enough to provide real diversification benefit when combined.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.50 |
Correlation (All Time) Calculated using the full available price history since Jun 30, 2023 | 0.55 |
The correlation between SBIO.L and FWRA.L has been stable across timeframes, ranging from 0.50 to 0.55 - a consistent structural relationship.
SBIO.L vs. FWRA.L - Sectors Allocation Comparison
Sectors
SBIO.L
FWRA.L
Healthcare
Basic Materials
-
Communication Services
-
Consumer Cyclical
-
Consumer Defensive
-
Energy
-
Financial Services
-
Industrials
-
Real Estate
-
Technology
-
Utilities
-
Healthcare
SBIO.L
FWRA.L
Basic Materials
SBIO.L
-
FWRA.L
Communication Services
SBIO.L
-
FWRA.L
Consumer Cyclical
SBIO.L
-
FWRA.L
Consumer Defensive
SBIO.L
-
FWRA.L
Energy
SBIO.L
-
FWRA.L
Financial Services
SBIO.L
-
FWRA.L
Industrials
SBIO.L
-
FWRA.L
Real Estate
SBIO.L
-
FWRA.L
Technology
SBIO.L
-
FWRA.L
Utilities
SBIO.L
-
FWRA.L
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
SBIO.L vs. FWRA.L — Risk / Return Rank
SBIO.L
FWRA.L
SBIO.L vs. FWRA.L - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Invesco Nasdaq Biotech UCITS ETF (SBIO.L) and Invesco FTSE All-World UCITS ETF USD Accumulation (FWRA.L). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| SBIO.L | FWRA.L | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -0.23 | ||
| Sortino ratioReturn per unit of downside risk | -0.43 | ||
| Omega ratioGain probability vs. loss probability | 1.35 | 1.43 | -0.08 |
| Calmar ratioReturn relative to maximum drawdown | 5.38 | 3.27 | +2.11 |
| Martin ratioReturn relative to average drawdown | 16.56 | 13.70 | +2.85 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading charts...
Sharpe Ratios by Period
| SBIO.L | FWRA.L | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 2.09 | 2.32 | -0.23 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | 0.22 | — | — |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | 0.34 | — | — |
Sharpe Ratio (All Time)Calculated using the full available price history | 0.27 | 1.56 | -1.29 |
Drawdowns
SBIO.L vs. FWRA.L - Drawdown Comparison
The maximum SBIO.L drawdown since its inception was -39.44%, which is greater than FWRA.L's maximum drawdown of -16.60%. Use the drawdown chart below to compare losses from any high point for SBIO.L and FWRA.L.
Loading charts...
Drawdown Indicators
| SBIO.L | FWRA.L | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -39.44% | -16.60% | -22.84% |
Max Drawdown (1Y)Largest decline over 1 year | -7.64% | -8.74% | +1.10% |
Max Drawdown (3Y)Largest decline over 3 years | -26.88% | — | — |
Max Drawdown (5Y)Largest decline over 5 years | -38.33% | — | — |
Max Drawdown (10Y)Largest decline over 10 years | -38.33% | — | — |
Current DrawdownCurrent decline from peak | -2.84% | -0.77% | -2.07% |
Average DrawdownAverage peak-to-trough decline | -16.83% | -1.93% | -14.90% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 2.49% | 2.09% | +0.40% |
Volatility
SBIO.L vs. FWRA.L - Volatility Comparison
Invesco Nasdaq Biotech UCITS ETF (SBIO.L) has a higher volatility of 6.55% compared to Invesco FTSE All-World UCITS ETF USD Accumulation (FWRA.L) at 3.80%. This indicates that SBIO.L's price experiences larger fluctuations and is considered to be riskier than FWRA.L based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| SBIO.L | FWRA.L | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 6.55% | 3.80% | +2.75% |
Volatility (6M)Calculated over the trailing 6-month period | 15.27% | 9.86% | +5.41% |
Volatility (1Y)Calculated over the trailing 1-year period | 19.67% | 12.32% | +7.35% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 21.21% | 13.52% | +7.69% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 22.23% | 13.52% | +8.71% |
SBIO.L vs. FWRA.L - Expense Ratio Comparison
SBIO.L has a 0.40% expense ratio, which is higher than FWRA.L's 0.15% expense ratio.
Dividends
SBIO.L vs. FWRA.L - Dividend Comparison
Neither SBIO.L nor FWRA.L has paid dividends to shareholders.
Frequently Asked Questions
SBIO.L and FWRA.L have a correlation of 0.50, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
On fees, FWRA.L is cheaper at 0.15% per year. The better choice depends on whether you care most about return, fees, risk, or income.
FWRA.L is cheaper with a 0.15% expense ratio, compared with 0.40% for SBIO.L.
SBIO.L is categorized as Health & Biotech Equities, while FWRA.L is Global Equities. SBIO.L tracks NASDAQ Biotechnology TR USD, while FWRA.L tracks FTSE All-World Index. Their fees differ too: 0.40% for SBIO.L and 0.15% for FWRA.L.
Find the right allocation for SBIO.L and FWRA.L
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer